Hisoar Pharmaceutical buys back shares, boosts market confidence

Zhejiang Hisoar Pharmaceutical announced progress in its share repurchase program, which began on April 9, 2025. As of April 10, 2025, the company had repurchased 15,000 shares through centralized bidding, totaling CNY 7.46 million. This represents about 0.003% of the company's total share capital. The highest price paid per share was CNY 500, with the lowest being CNY 490.

The board of directors approved a repurchase program for shares valued between CNY 30 million and CNY 60 million, with a price cap of CNY 600 per share. This program aims to enhance investor confidence and stabilize the stock price. The repurchased shares will be used for employee stock ownership plans or equity incentives, directly benefiting the company's workforce.

The company is committed to adhering to relevant laws and regulations, including Shenzhen Stock Exchange rules, throughout the repurchase process. The announcement also noted the company has not engaged in share repurchases within the last six months, and no connected parties participated in the current repurchase.